Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

In vivo Bioluminescence Imaging Used to Monitor Disease Activity and Therapeutic Response in a Mouse Model of Tauopathy.

Dunn-Meynell AA, Dowling P, Marchese M, Rodriguez E, Blumberg B, Choi YB, Gaindh D, Lu W.

Front Aging Neurosci. 2019 Sep 12;11:252. doi: 10.3389/fnagi.2019.00252. eCollection 2019.

2.

Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.

Gaindh D, Kavak KS, Teter B, Vaughn CB, Cookfair D, Hahn T, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium.

J Neurol Sci. 2016 Nov 15;370:13-17. doi: 10.1016/j.jns.2016.09.005. Epub 2016 Sep 9.

PMID:
27772741
3.

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.

Chiu AW, Richert N, Ehrmantraut M, Ohayon J, Gupta S, Bomboi G, Gaindh D, Cantor FK, Frank JA, McFarland HF, Bagnato F.

Arch Neurol. 2009 Jan;66(1):39-43. doi: 10.1001/archneur.66.1.noc80047. Epub 2008 Nov 10.

PMID:
19001157
4.

The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.

Gaindh D, Jeffries N, Ohayon J, Richert ND, Pellicano C, Frank JA, McFarland H, Bagnato F.

Expert Opin Biol Ther. 2008 Dec;8(12):1823-9. doi: 10.1517/14712590802510629 .

5.

The effect of interferon-beta on black holes in patients with multiple sclerosis.

Bagnato F, Evangelou IE, Gallo A, Gaindh D, Yao K.

Expert Opin Biol Ther. 2007 Jul;7(7):1079-91. Review.

PMID:
17665995

Supplemental Content

Loading ...
Support Center